Reisa Sperling
Sperling, Reisa
VIAF ID: 36692715 (Personal)
Permalink: http://viaf.org/viaf/36692715
Preferred Forms
-
100 0 _ ‡a Reisa Sperling
-
100 1 _ ‡a Sperling, Reisa
-
100 1 _ ‡a Sperling, Reisa
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors |
![]() |
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. |
![]() |
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials |
![]() |
Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent? |
![]() |
Assessment of cognition in early dementia. |
![]() |
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. |
![]() |
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. |
![]() |
Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. |
![]() |
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. |
![]() |
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies |
![]() |
Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study |
![]() |
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. |
![]() |
Defeating Alzheimer's disease and other dementias: a priority for European science and society. |
![]() |
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. |
![]() |
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants |
![]() |
Epicenters of dynamic connectivity in the adaptation of the ventral visual system. |
![]() |
The evolution of preclinical Alzheimer's disease: implications for prevention trials. |
![]() |
Functional MRI detection of pharmacologically induced memory impairment. |
![]() |
Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. |
![]() |
Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. |
![]() |
Implementation of subjective cognitive decline criteria in research studies. |
![]() |
In vivo characterization of the early states of the amyloid-beta network. |
![]() |
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. |
![]() |
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease |
![]() |
Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: variations on the same ARIA? |
![]() |
Mapping the road forward in Alzheimer's disease. |
![]() |
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
![]() |
On the path to 2025: understanding the Alzheimer's disease continuum. |
![]() |
Potential of functional MRI as a biomarker in early Alzheimer's disease |
![]() |
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. |
![]() |
Pro: Can biomarkers be gold standards in Alzheimer's disease? |
![]() |
Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation |
![]() |
Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. |
![]() |
Research priorities to reduce the global burden of dementia by 2025. |
![]() |
The role of neuroimaging in elucidating delirium pathophysiology. |
![]() |
Scientific American frontiers. Don't forget! [VR] c2005: |
![]() |
Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease |
![]() |
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. |
![]() |
Tau positron emission tomographic imaging in aging and early Alzheimer disease |
![]() |
Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. |
![]() |
To sleep, perchance to delay dementia. |
![]() |
Two macroscopic and microscopic brain imaging studies of human hippocampus in early Alzheimer's disease and schizophrenia research. |
![]() |
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. |
![]() |
Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. |
![]() |